Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.63 |
| ▸ | ALDH3A1 | P30838 | 7/20 | 0.63 |
| ▸ | ALDH2 | P05091 | 5/20 | 0.63 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628082 | 0.86 | ALDH1A1 (0.46) | ALDH1A1ALDH3A1ALDH2CUL4ACES1 | |
| SCHEMBL17830712 | 0.86 | PARK7 (0.60) | ALDH1A1ALDH3A1KMT2APARK7CTRB1 | |
| SCHEMBL17830710 | 0.86 | ALDH1A1 (0.64) | ALDH1A1ALDH3A1ALDH2KMT2APARK7 | |
| SCHEMBL12674685 | 0.83 | ALDH1A1 (0.76) | ALDH1A1ALDH3A1ALDH2CUL4ACES1 | |
| SCHEMBL13637635 | 0.80 | ALDH1A1 (0.39) | ALDH1A1ALDH3A1ALDH2CUL4ACTRB1 | |
| SCHEMBL17830744 | 0.78 | ALDH1A1 (0.55) | ALDH1A1ALDH3A1ALDH2CUL4ACES1 | |
| SCHEMBL5659265 | 0.78 | ALDH1A1 (1.00) | ALDH1A1ALDH3A1ALDH2CUL4ACES1 | |
| SCHEMBL17830745 | 0.78 | ALDH1A1 (0.56) | ALDH1A1ALDH3A1ALDH2KMT2A | |
| SCHEMBL17830707 | 0.76 | APEX1 (0.61) | KMT2A | |
| SCHEMBL16799029 | 0.76 | ALDH1A1 (1.00) | ALDH1A1ALDH3A1ALDH2CUL4ACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | ALDH1A1 4832/4885ALDH3A1 4762/4885ALDH2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.